TY - JOUR AU - Gaál, Szilvia AU - Kahán, Zsuzsanna AU - Rárosi, Ferenc AU - Fodor, Gergely AU - Tolnai, József AU - Deák , Bence AU - Hideghéty, Katalin AU - Varga, Zoltán TI - Individual benefit in heart sparing during DIBH-supported left breast radiotherapy JF - CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY J2 - CLIN TRANSL RADIAT ONCOL (CTRO) VL - 46 PY - 2024 PG - 9 SN - 2405-6308 DO - 10.1016/j.ctro.2024.100746 UR - https://m2.mtmt.hu/api/publication/34684406 ID - 34684406 LA - English DB - MTMT ER - TY - JOUR AU - Pascual, Javier AU - Gil-Gil, Miguel AU - Proszek, Paula AU - Zielinski, Christoph AU - Reay, Alistair AU - Ruiz-Borrego, Manuel AU - Cutts, Rosalind AU - Ciruelos Gil, Eva M AU - Feber, Andrew AU - Muñoz-Mateu, Montserrat AU - Swift, Claire AU - Bermejo, Begoña AU - Herranz, Jesus AU - Margeli Vila, Mireia AU - Antón, Antonio AU - Kahán, Zsuzsanna AU - Csöszi, Tibor AU - Liu, Yuan AU - Fernandez-Garcia, Daniel AU - Garcia-Murillas, Isaac AU - Hubank, Michael AU - Turner, Nicholas C AU - Martín, Miguel TI - Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients JF - CLINICAL CANCER RESEARCH J2 - CLIN CANCER RES VL - 29 PY - 2023 IS - 20 SP - 4166 EP - 4177 PG - 12 SN - 1078-0432 DO - 10.1158/1078-0432.CCR-23-0956 UR - https://m2.mtmt.hu/api/publication/34513250 ID - 34513250 AB - Prognostic and predictive biomarkers to cyclin-dependent kinases 4 and 6 inhibitors are lacking. Circulating tumor DNA (ctDNA) can be used to profile these patients and dynamic changes in ctDNA could be an early predictor of treatment efficacy. Here, we conducted plasma ctDNA profiling in patients from the PEARL trial comparing palbociclib+fulvestrant versus capecitabine to investigate associations between baseline genomic landscape and on-treatment ctDNA dynamics with treatment efficacy.Correlative blood samples were collected at baseline [cycle 1-day 1 (C1D1)] and prior to treatment [cycle 1-day 15 (C1D15)]. Plasma ctDNA was sequenced with a custom error-corrected capture panel, with both univariate and multivariate Cox models used for treatment efficacy associations. A prespecified methodology measuring ctDNA changes in clonal mutations between C1D1 and C1D15 was used for the on-treatment ctDNA dynamic model.201 patients were profiled at baseline, with ctDNA detection associated with worse progression-free survival (PFS)/overall survival (OS). Detectable TP53 mutation showed worse PFS and OS in both treatment arms, even after restricting population to baseline ctDNA detection. ESR1 mutations were associated with worse OS overall, which was lost when restricting population to baseline ctDNA detection. PIK3CA mutations confer worse OS only to patients on the palbociclib+fulvestrant treatment arm. ctDNA dynamics analysis (n = 120) showed higher ctDNA suppression in the capecitabine arm. Patients without ctDNA suppression showed worse PFS in both treatment arms.We show impaired survival irrespective of endocrine or chemotherapy-based treatments for patients with hormone receptor-positive/HER2-negative metastatic breast cancer harboring plasma TP53 mutations. Early ctDNA suppression may provide treatment efficacy predictions. Further validation to fully demonstrate clinical utility of ctDNA dynamics is warranted. LA - English DB - MTMT ER - TY - JOUR AU - Pipek, Orsolya Anna AU - Alpár, Donát AU - Rusz, Orsolya AU - Bödör, Csaba AU - Udvarnoki, Zoltán András AU - Medgyes-Horváth, Anna AU - Csabai, István AU - Szállási, Zoltán AU - Madaras, Lilla AU - Kahán, Zsuzsanna AU - Cserni, Gábor AU - Kővári, Bence AU - Kulka, Janina AU - Tőkés, Anna-Mária TI - Genomic Landscape of Normal and Breast Cancer Tissues in a Hungarian Pilot Cohort JF - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES J2 - INT J MOL SCI VL - 24 PY - 2023 IS - 10 PG - 19 SN - 1661-6596 DO - 10.3390/ijms24108553 UR - https://m2.mtmt.hu/api/publication/33814839 ID - 33814839 N1 - Funding Agency and Grant Number: NKFIH, Hungary [FK20-134253, K21-137948, TKP2021-EGA-24, TKP2021-NVA-15, NVKP-16-1-2016-0004]; EU's Horizon 2020 research and innovation program [739593]; Janos Bolyai Research Scholarship program of the Hungarian Academy of Sciences [BO/00125/22]; New National Excellence Program of the Ministry for Innovation and Technology [UNKP-22-5-SE-7]; Complementary Research Excellence Program; Kerpel Talent Award of Semmelweis University [EFOP-3.6.3-VEKOP-16-2017-00009]; ELIXIR Hungary Funding text: This study was supported by the following grants: NKFIH, Hungary: FK20-134253, K21-137948, TKP2021-EGA-24, TKP2021-NVA-15 and NVKP-16-1-2016-0004. The study was also supported by the EU's Horizon 2020 research and innovation program (No. 739593), the Janos Bolyai Research Scholarship program (BO/00125/22) of the Hungarian Academy of Sciences, the UNKP-22-5-SE-7 grant of the New National Excellence Program of the Ministry for Innovation and Technology, by the Complementary Research Excellence Program, the Kerpel Talent Award of Semmelweis University (EFOP-3.6.3-VEKOP-16-2017-00009), and the ELIXIR Hungary. AB - A limited number of studies have focused on the mutational landscape of breast cancer in different ethnic populations within Europe and compared the data with other ethnic groups and databases. We performed whole-genome sequencing of 63 samples from 29 Hungarian breast cancer patients. We validated a subset of the identified variants at the DNA level using the Illumina TruSight Oncology (TSO) 500 assay. Canonical breast-cancer-associated genes with pathogenic germline mutations were CHEK2 and ATM. Nearly all the observed germline mutations were as frequent in the Hungarian breast cancer cohort as in independent European populations. The majority of the detected somatic short variants were single-nucleotide polymorphisms (SNPs), and only 8% and 6% of them were deletions or insertions, respectively. The genes most frequently affected by somatic mutations were KMT2C (31%), MUC4 (34%), PIK3CA (18%), and TP53 (34%). Copy number alterations were most common in the NBN, RAD51C, BRIP1, and CDH1 genes. For many samples, the somatic mutational landscape was dominated by mutational processes associated with homologous recombination deficiency (HRD). Our study, as the first breast tumor/normal sequencing study in Hungary, revealed several aspects of the significantly mutated genes and mutational signatures, and some of the copy number variations and somatic fusion events. Multiple signs of HRD were detected, highlighting the value of the comprehensive genomic characterization of breast cancer patient populations. LA - English DB - MTMT ER - TY - JOUR AU - Rubovszky, Gábor AU - Kocsis, Judit AU - Boér, Katalin AU - Chilingirova, Nataliya AU - Dank, Magdolna AU - Kahán, Zsuzsanna AU - Kaidarova, Dilyara AU - Kövér, Erika AU - Krakovská, Bibiana Vertáková AU - Máhr, Károly AU - Mriňáková, Bela AU - Pikó, Béla AU - Božović-Spasojević, Ivana AU - Horváth, Zsolt TI - Corrigendum : Systemic treatment of breast cancer. 1st Central-Eastern European professional Consensus Statement on breast cancer JF - PATHOLOGY AND ONCOLOGY RESEARCH J2 - PATHOL ONCOL RES VL - 29 PY - 2023 PG - 2 SN - 1219-4956 DO - 10.3389/pore.2023.1610954 UR - https://m2.mtmt.hu/api/publication/33647465 ID - 33647465 LA - English DB - MTMT ER - TY - JOUR AU - Kahán, Zsuzsanna AU - Szanto, Istvan AU - Dudas, Rita AU - Kapitány, Zsuzsanna AU - Molnar, Maria AU - Koncz, Zsuzsa AU - Mailáth, Mónika ED - Krenács, Tibor / Collaborator ED - Kulka, Janina / Collaborator ED - Dank, Magdolna / Collaborator ED - Polgár, Csaba / Collaborator ED - Kapitány, Zsuzsanna / Collaborator ED - Koncz, Zsuzsa / Collaborator TI - Breast Cancer Survivorship Programme: Follow-Up, Rehabilitation, Psychosocial Oncology Care. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer JF - PATHOLOGY AND ONCOLOGY RESEARCH J2 - PATHOL ONCOL RES VL - 28 PY - 2022 PG - 14 SN - 1219-4956 DO - 10.3389/pore.2022.1610391 UR - https://m2.mtmt.hu/api/publication/32961748 ID - 32961748 N1 - Department of Oncotherapy, University of Szeged, Szeged, Hungary St. George’s General Teaching Hospital, Székesfehérvár, Hungary Department of Physiotherapy, Semmelweis University, Budapest, Hungary Oncoradiology Centre, Bács-Kiskun County Hospital, Kecskemét, Hungary Institute of Behavioural Sciences, Semmelweis University, Budapest, Hungary Institute of Oncology, University of Debrecen, Debrecen, Hungary Cited By :5 Export Date: 4 April 2024 CODEN: POREF Correspondence Address: Kahán, Z.; Department of Oncotherapy, Hungary; email: kahan.zsuzsanna@med.u-szeged.hu Chemicals/CAS: tamoxifen, 10540-29-1; trastuzumab, 180288-69-1, 1446410-98-5 AB - Follow-up includes ongoing contact with and health education of the patient, surveillance and control of the adverse effects of surgery, oncological therapies or radiotherapy, screening of metachronous cancers, and comprehensive (physical, psychological and social) patient rehabilitation, which may be enhanced by a healthy lifestyle. Primary attention should be paid to early detection and, when needed, curative treatment of local/regional tumour recurrences. Similarly, with the hope of curative solution, it is important to recognize the entity of a low-mass and relatively indolent recurrence or metastasis (oligometastasis); however, there is still no need to investigate distant metastases by routine diagnostic imaging or assess tumour markers. Below there is a list of possible sources of support, with respect to adjuvant hormone therapy continued during long-term care, social support resources, pivotal points and professional opportunities for physical and mental rehabilitation. Individual solutions for specific issues (breast cancer risk/genetic mutation, pregnancy) are provided by constantly widening options. Ideally, a complex breast cancer survivorship programme is practised by a specially trained expert supported by a cooperative team of oncologists, surgeons, breast radiologists, social workers, physiotherapists, psycho-oncologists and psychiatrists. The approach of follow-up should be comprehensive and holistic. LA - English DB - MTMT ER - TY - JOUR AU - Kahán, Zsuzsanna TI - Diversity of breast cancers begins at imaging... JF - EUROPEAN JOURNAL OF RADIOLOGY J2 - EUR J RADIOL VL - 154 PY - 2022 PG - 3 SN - 0720-048X DO - 10.1016/j.ejrad.2022.110362 UR - https://m2.mtmt.hu/api/publication/32952088 ID - 32952088 LA - English DB - MTMT ER - TY - JOUR AU - Rubovszky, Gábor AU - Kocsis, Judit AU - Boér, Katalin AU - Chilingirova, Nataliya AU - Dank, Magdolna AU - Kahán, Zsuzsanna AU - Kaidarova, Dilyara AU - Kövér, Erika AU - Krakovská, Bibiana Vertáková AU - Máhr, Károly AU - Mriňáková, Bela AU - Pikó, Béla AU - Božović-Spasojević, Ivana AU - Horváth, Zsolt ED - Krenács, Tibor / Collaborator ED - Kulka, Janina / Collaborator ED - Dank, M / Collaborator ED - Polgár, Csaba / Collaborator ED - Kapitány, Zsuzsanna / Collaborator ED - Koncz, Zsuzsa / Collaborator TI - Systemic Treatment of Breast Cancer. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer JF - PATHOLOGY AND ONCOLOGY RESEARCH J2 - PATHOL ONCOL RES VL - 28 PY - 2022 PG - 26 SN - 1219-4956 DO - 10.3389/pore.2022.1610383 UR - https://m2.mtmt.hu/api/publication/32946435 ID - 32946435 N1 - Funding Agency and Grant Number: Central Eastern European Academy of Oncology Foundation; National Institute of Oncology Funding text: The publication fee is covered by funding of the Central Eastern European Academy of Oncology Foundation, National Institute of Oncology 1122 Budapest Rath Gy. u 7-9. LA - English DB - MTMT ER - TY - JOUR AU - Polgár, Csaba AU - Kahán, Zsuzsanna AU - Ivanov, Olivera AU - Chorváth, Martin AU - Ligačová, Andrea AU - Csejtei, András AU - Gábor, Gabriella AU - Landherr, László AU - Mangel, László Csaba AU - Mayer, Árpád AU - Fodor, János TI - Radiotherapy of Breast Cancer—Professional Guideline 1st Central-Eastern European Professional Consensus Statement on Breast Cancer JF - PATHOLOGY AND ONCOLOGY RESEARCH J2 - PATHOL ONCOL RES VL - 28 PY - 2022 PG - 15 SN - 1219-4956 DO - 10.3389/pore.2022.1610378 UR - https://m2.mtmt.hu/api/publication/32913015 ID - 32913015 AB - The international radiotherapy (RT) expert panel has revised and updated the RT guidelines that were accepted in 2020 at the 4th Hungarian Breast Cancer Consensus Conference, based on new scientific evidence. Radiotherapy after breast-conserving surgery (BCS) is indicated in ductal carcinoma in situ (stage 0), as RT decreases the risk of local recurrence (LR) by 50-60%. In early stage (stage I-II) invasive breast cancer RT remains a standard treatment following BCS. However, in elderly (≥70 years) patients with stage I, hormone receptor-positive tumour, hormonal therapy without RT can be considered. Hypofractionated whole breast irradiation (WBI) and for selected cases accelerated partial breast irradiation are validated treatment alternatives to conventional WBI administered for 5 weeks. Following mastectomy, RT significantly decreases the risk of LR and improves overall survival of patients who have 1 to 3 or ≥4 positive axillary lymph nodes. In selected cases of patients with 1 to 2 positive sentinel lymph nodes axillary dissection can be substituted with axillary RT. After neoadjuvant systemic treatment (NST) followed by BCS, WBI is mandatory, while after NST followed by mastectomy, locoregional RT should be given in cases of initial stage III-IV and ypN1 axillary status. LA - English DB - MTMT ER - TY - JOUR AU - Nagy, Zoltán AU - Laboda, Brigitta AU - Antal, Gergely AU - Toller, Gábor AU - Kahán, Zsuzsanna AU - Cselik, Zsolt TI - Brachyterápiás Acuros BV és TG-43 formalizmus összehasonlítása HDR cervixkezeléseknél JF - MAGYAR ONKOLÓGIA J2 - MAGYAR ONKOLÓGIA VL - 66 PY - 2022 IS - 1 SP - 74 EP - 74 PG - 1 SN - 0025-0244 UR - https://m2.mtmt.hu/api/publication/32838847 ID - 32838847 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Martin, M. AU - Zielinski, C. AU - Ruiz-Borrego, M. AU - Carrasco, E. AU - Turner, N. AU - Ciruelos, E.M. AU - Muñoz, M. AU - Bermejo, B. AU - Margeli, M. AU - Anton, A. AU - Kahán, Zsuzsanna AU - Csöszi, T. AU - Casas, M.I. AU - Murillo, L. AU - Morales, S. AU - Alba, E. AU - Gal-Yam, E. AU - Guerrero-Zotano, A. AU - Calvo, L. AU - de la Haba-Rodriguez, J. AU - Ramos, M. AU - Alvarez, I. AU - Garcia-Palomo, A. AU - Huang Bartlett, C. AU - Koehler, M. AU - Caballero, R. AU - Corsaro, M. AU - Huang, X. AU - Garcia-Sáenz, J.A. AU - Chacón, J.I. AU - Swift, C. AU - Thallinger, C. AU - Gil-Gil, M. TI - Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL JF - ANNALS OF ONCOLOGY J2 - ANN ONCOL VL - 32 PY - 2021 IS - 4 SP - 488 EP - 499 PG - 12 SN - 0923-7534 DO - 10.1016/j.annonc.2020.12.013 UR - https://m2.mtmt.hu/api/publication/32546756 ID - 32546756 N1 - Funding Agency and Grant Number: PfizerPfizer; AstraZenecaAstraZeneca; GEICAM Spanish Breast Cancer Group Funding text: This work was supported by two funding companies: Pfizer (that provided palbociclib and exemestane) and study grant (no grant number) and AstraZeneca (that provided fulvestrant). The trial sponsor is GEICAM Spanish Breast Cancer Group. The corresponding author had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The content is solely the responsibility of the authors. LA - English DB - MTMT ER -